secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001001233-25-000011
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025
----------------------------------------------------------------------------

- Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.
- She will transition to part-time employment and remain interim principal financial officer until a successor is appointed.
- Company thanks Duraibabu for contributions to strategic collaborations and investment allocations positioning Sangamo as a neurology-focused genomic medicines company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000100123325000011/0001001233-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000100123325000011/sgmo-20250909.htm
  HTML page:      https://secwatch.observer/filing/0001001233-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer